Skip to main content
SpringerLink
Log in

Counseling the Patient on Choice of Therapy and Outcomes

Surgeon’s Perspective

  • Chapter
Management of Prostate Cancer

Part of the book series: Current Clinical Urology ((CCU))

  • 116 Accesses

Abstract

With over 209,000 new cases diagnosed in 1997, prostate cancer remains the most common cancer diagnosed in American men (1). Because of the possibility that a patient, friend, or relative could be affected, counseling about treatment options becomes a central issue not only for urologists, but also for most physicians. Advances in the diagnosis of this disease with prostate-specific antigen (PSA) testing have been paralleled by improvements in therapy. These include improvements in both external beam radiotherapy and surgery, a potential rebirth of cryosurgery and prostate brachytherapy, and various combinations. However, the optimal treatment modality (or whether treatment is required at all) for an individual patient is highly debatable, and different “experts” may give different opinions. These factors make counseling the patient extremely difficult, and make the patient’s decision equally or more difficult. Conflicting advice can overwhelm and confuse a patient. In this chapter, our approach to counseling the patient is presented. The approach seeks to provide balanced information, which we believe supports radical surgery in men with longer life expectancy, but strives to help the patient make the best decision for his situation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Wingo PA, Landis S, Ries LAG. An adjustment to the 1997 estimate for new cancer cases. CA Cancer J Clin 1997; 47: 239–242.

    Article  PubMed  CAS  Google Scholar 

  2. Moore MJ, O’Sullivan B, Tannock IF. How expert physicians would choose to be treated if they had genitourinary cancer. J Clin Oncol 1988; 6: 1736–1745.

    PubMed  CAS  Google Scholar 

  3. American Foundation for Urologic Disease. Prostate Cancer Resource Guide. Baltimore, MD, 1997.

    Google Scholar 

  4. Franks LM. Latent carcinoma of the prostate. J Pathol Bacteriol 1954; 68: 603–616.

    Article  PubMed  CAS  Google Scholar 

  5. Stamey TA. Prostate cancer: who should be treated? Monogr Urol 1995; 16: 1–16.

    Google Scholar 

  6. Smith DS, Catalona WJ. The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994; 152: 1732–1736.

    PubMed  CAS  Google Scholar 

  7. US Bureau of the Census. Life tables. In: Vital Statistics of the United States. Washington DC, section 6:1–19, section 7:22–23, 1990.

    Google Scholar 

  8. Walsh PC. The natural history of localized prostate cancer: a guide to therapy. In: Walsh PC, et al., eds. Campbell’s Urology. WB Saunders, Philadelphia, PA, 1997, pp. 2539–2546.

    Google Scholar 

  9. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage and gleason score to predict pathological stage of localized prostate cancer. JAMA 1997; 277: 1445–1451.

    Article  PubMed  CAS  Google Scholar 

  10. Chodak GW, Thistead TA, Gerber GS, Johansson J-E, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242–248.

    Article  PubMed  CAS  Google Scholar 

  11. Albertsen P, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated prostate cancer. JAMA 1995; 274: 626–631.

    Article  PubMed  CAS  Google Scholar 

  12. Johansson J-E, Holmberg L, Johansson S, Bergstrom R, Adami H-O. Fifteen-year survival in prostate cancer: A prospective population based study in Sweden. JAMA 1997; 277: 467–471.

    CAS  Google Scholar 

  13. Aus G, Hugossun J, Norlen L. Long-term survival and mortality in prostate cancer treated with non-curative intent. J Urol 19XX; 154: 460–465.

    Google Scholar 

  14. Shinohara K, Rhee B, Presti JC, Carroll PR. Cryosurgical ablation of prostate cancer: patterns of cancer recurrence. J Urol 1997; 158: 2206–2210.

    Article  PubMed  CAS  Google Scholar 

  15. Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology 1996; 47: 395–401.

    Article  PubMed  CAS  Google Scholar 

  16. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, et al. Interstitial Iodine-125 Radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer 1997; 80: 442–453.

    Article  PubMed  CAS  Google Scholar 

  17. Beyer DC, Priestley JB. Biochemical disease-free survival following 125-I prostate implantation. Int J Radiat Oncol Biol Phys 1997; 37: 559–563.

    Article  PubMed  CAS  Google Scholar 

  18. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy gleason grade in academic and community settings. Am J Surg Pathol 1997; 21: 566–576.

    Article  PubMed  CAS  Google Scholar 

  19. Polascik TJ, Pound CR, Deweese TL, Walsh PC. Comparision of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. Urology 1998; 51: 884–890.

    Article  PubMed  CAS  Google Scholar 

  20. Moerland MA, Wijrdeman HK, Boersma R, Bakker CJ, Batterman JJ. Evaluation of permanent Iodine-125 prostate implants using radiography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 1997; 37: 927–933.

    Article  PubMed  CAS  Google Scholar 

  21. Hanks GE, Hanlon AL, Schultheiss TE, Freedman GM, Hunt M, Pinover WH, et al. Conformal external beam treatment of prostate cancer. Urology 1997; 50: 87–92.

    Article  PubMed  CAS  Google Scholar 

  22. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, Strawderman MS, Grijalva KH, Kish KE, et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 1997; 38: 311–317.

    Article  PubMed  CAS  Google Scholar 

  23. Damico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malcowicz SB, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of 4–20 ng/ml. Int J Radiat Oncol Biol Phys 1997; 37: 1053–1058.

    Article  CAS  Google Scholar 

  24. Pound CR, Partin AW, Epstein JI, Walsh PC. Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Am. 1997; 24: 395–406.

    Article  PubMed  CAS  Google Scholar 

  25. Zincke H, Bergstralh EJ, Blute ML, Myers RP, Barrett DM, Lieber MM, et al. Radical prostatectomy for clinically localized prostate cancer-long term results of 1143 patients from a single institution. J Clin Oncol 1994; 12: 2254–2263.

    PubMed  CAS  Google Scholar 

  26. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1035–1041.

    Google Scholar 

  27. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA. Stage T1–2 prostate cancer with pretreatment prostate-specific antigen level lt<10 ng/mL: radiation therapy or surgery. Int J Radiat Oncol Biol Phys 1997; 38: 723–729.

    Article  PubMed  CAS  Google Scholar 

  28. Critz F, Levinson A, Williams W, et al. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer. Urology 1997; 49: 322–326.

    Article  PubMed  CAS  Google Scholar 

  29. Vashi AR, Oesterling JE. Radical retropubic prostatectomy for localised prostate cancer. In: Kaisary AV, et al., ed. Textbook of Prostate Cancer. Martin Dunitz, London, in press.

    Google Scholar 

  30. Eggleston JC, Walsh PC. Radical prostatectomy with preservation of sexual function: pathological findings in the first 100 cases. J Urol 1985; 134: 1146–1148.

    PubMed  CAS  Google Scholar 

  31. Stamey TA, Ferrari MK, Scmid HP. The value of serial prostate-specific antigen determinations 5 years after radiotherapy: Steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1856–1859.

    PubMed  CAS  Google Scholar 

  32. Schellhammer PF, El-Mandi AM, Wright GL, Kolm P, Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 1993; 42: 13–20.

    Article  PubMed  CAS  Google Scholar 

  33. Kupelian P, Katcher J, Zippe C, et al. External beam radiotherapy vs. radical prostatectomy for clinical T1–2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy gleason scores. Cancer J Sci Am 1997; 3: 1–10.

    Google Scholar 

  34. Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, et al. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys 1997; 37: 543–550.

    Article  PubMed  CAS  Google Scholar 

  35. Pilepich MJ, Krall JM, Al-Sarraf M, et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: A randomized comparitive trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616–623.

    Article  PubMed  CAS  Google Scholar 

  36. Blasko JC, Radge H, Cavanaugh W, et al. Long-term outcomes of external beam irradiation and I-125/ Pd-103 brachytherapy boost for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 36: 193–198.

    Article  Google Scholar 

  37. Herr HW, Kornblith AB, Ofman U. A comparision of quality of life of patients with metastatic prostate cancer who received or did not receive hormonal therapy. Cancer 1993; 71: 1143–1150.

    Article  PubMed  CAS  Google Scholar 

  38. Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE. Health-related quality of life among patients with metastatic prostate cancer. Urology 1997; 49: 207–217.

    Article  PubMed  CAS  Google Scholar 

  39. Toy PT, Menozzi D, Strauss RG, Stehlinng LC, Kruskall M, Ahn DK. Efficacy of preoperative donation of blood for autologous use in radical prostatectomy. Transfusion 1993; 33: 721–724.

    Article  PubMed  CAS  Google Scholar 

  40. Ness PM, Baldwin ML, Walsh PC. Pre-deposit autologous transfusion in radical retropubic prostatectomy. Transfusion 1987; 27: 518A.

    Google Scholar 

  41. Goh M, Kleer CG, Kielczewski PA, Wojno KJ, Kim KM, Oesterling JE. Autologous blood donation prior to anatomical radical prostatectomy. Is it really necessary? Urology 1997; 49: 569–574.

    Article  PubMed  CAS  Google Scholar 

  42. Walsh PC, Partin AW, Epstein JI. Cancer control and quality of life following anatomical radical prostatectomy: results at ten years. J Urol 1994; 152: 1831–1836.

    PubMed  CAS  Google Scholar 

  43. Catalona WJ, Bigg SW. Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. J Urol 1989; 143: 538–542.

    Google Scholar 

  44. Fowler FJ, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE. Patient-reported complications and follow-up treatment after radical prostatectomy: the national Medicare experience: 1988–1990. Urology 1993; 42: 622–629.

    Article  PubMed  Google Scholar 

  45. Fowler FJ, Barry MJ, Lu-Yao G, Wasson J, Bin L. Outcomes of external-beam radiation therapy for prostate cancer: A study of Medicare beneficiaries in three surveillance, epidemiology and end results areas. J Clin Oncol 1996; 14: 2258–2265.

    PubMed  Google Scholar 

  46. Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129–135.

    Article  PubMed  CAS  Google Scholar 

  47. Shrader-Bogen CL, Kjellberg JL, McPherson CP, Murray CL. Quality of life and treatment outcomes: prostate carcinoma patient’ s perspectives after prostatectomy or radiation therapy. Cancer 1997; 79: 1977–1986.

    Article  PubMed  CAS  Google Scholar 

  48. Sanda MG, Wei JT, King K, Oesterling JE, Montie JE. Prospective longitudinal analysis of patient reported outcomes following radical prostatectomy. J Urol 1998; 159 (Suppl): 231A.

    Article  Google Scholar 

  49. Pontes JE, Montie J, Klein E, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 1993; 71: 976–980.

    Article  PubMed  CAS  Google Scholar 

  50. Forman JD, Velasco J. Therapeutic radiation in patie nts with a rising post-prostatectomy PSA level. Oncology 1998; 12: 33–39.

    PubMed  CAS  Google Scholar 

  51. Cadeddu JA, Partin AW, DeWeese TL, Walsh PC. Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 1998; 159: 173–178.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Apoorva R. Vashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James E. Montie
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Urologic Oncology, Department of Urology, Cleveland Clinic Foundation, Cleveland, OH, USA

    Eric A. Klein MD

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Vashi, A.R., Montie, J.E. (2000). Counseling the Patient on Choice of Therapy and Outcomes. In: Klein, E.A. (eds) Management of Prostate Cancer. Current Clinical Urology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-714-7_19

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-714-7_19

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9826-4

  • Online ISBN: 978-1-59259-714-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation